Tech Seeker (TS)

Profile last edited on: 3/23/2022

Specialty prescription products plus large/established line of OTC and BTC products.
TS Type
Mid-sized Corporation: foreign
Year Founded
Last Involved Year

Key People / Management

  Jean-François Lemieux -- National Sales Director

  Sean A MacDonald -- Director, Business Development

  Frank Puglisi -- Senior Director, Head of Business Development

  Elise Vézina -- Vice-President & Division Head

Location Information

6111 Royalmount Avenue
Montreal Quebec, CN H4P 2T4
   (514) 340-5045

Public Profile

PENDOPHARM, Division of Pharmascience Inc. Established in 1983 and privately-owned, With a strong focus on specialty Mmedicines PENDOPHARM is a rapidly growing, independent business focused on commercializing a portfolio of specialty prescription products and an established line of OTC/BTC products. Strategically committed to growth, PENDOPHARM is actively engaged in licensing, developing and marketing late-stage prescription products as well as consumer brands. Partnership is a key component of the firmÂ’s growth strategy with a business model focused on developing long-term alliances that create synergistic value for both parties by aligning the firmÂ’s corporate capabilities, operations and resources to facilitate collaborations. The firm has the capability to provide expert regulatory filing, drug safety and medical information, logistics and distribution, customer service, manufacturing, sales/marketing, pricing, market access, and all other aspects of commercialization. Pharmascience Inc. is the largest pharmaceutical company in Quebec, with a highly skilled workforce of 1,300 people. Pharmascience commercializes nearly 300 products in over 1,000 formats, including generic, branded prescription, OTC and BTC products. In Canada alone, more than 21 million prescriptions a year are filled with Pharmascience products. Additionally, Pharmascience has a significant international presence, with 25% of its sales coming from 60 countries. Operationally, Pharmascience is fully integrated and controls all aspects of production, from manufacturing to commercialization. It has state-of-the-art laboratory, manufacturing and research & development facilities, with the capability of manufacturing capsules, tablets, suppositories, liquids and suspensions. Financially, Pharmascience is well capitalized and has consistently experienced double-digit growth, with current sales of Cnd$700 million.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

SBIR firms in the news

There are no news available.